Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aggression | 50 | 2022 | 323 | 8.660 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 32 | 2022 | 285 | 5.780 |
Why?
|
| Personality Disorders | 27 | 2020 | 145 | 5.000 |
Why?
|
| Impulsive Behavior | 26 | 2018 | 290 | 3.740 |
Why?
|
| Anger | 8 | 2021 | 81 | 1.490 |
Why?
|
| Oxytocin | 8 | 2020 | 73 | 1.300 |
Why?
|
| Serotonin | 11 | 2015 | 219 | 1.290 |
Why?
|
| Lysergic Acid Diethylamide | 5 | 2022 | 24 | 1.280 |
Why?
|
| Hallucinogens | 5 | 2022 | 77 | 1.270 |
Why?
|
| Social Perception | 5 | 2022 | 94 | 1.200 |
Why?
|
| Adult | 73 | 2022 | 27478 | 1.130 |
Why?
|
| Psychiatric Status Rating Scales | 21 | 2016 | 497 | 1.100 |
Why?
|
| Emotional Intelligence | 3 | 2016 | 22 | 1.070 |
Why?
|
| Young Adult | 37 | 2021 | 6597 | 1.020 |
Why?
|
| Emotions | 8 | 2022 | 360 | 1.010 |
Why?
|
| Child Abuse | 5 | 2014 | 86 | 1.000 |
Why?
|
| Psychometrics | 4 | 2016 | 335 | 0.990 |
Why?
|
| Borderline Personality Disorder | 4 | 2020 | 36 | 0.990 |
Why?
|
| Corticotropin-Releasing Hormone | 4 | 2011 | 44 | 0.940 |
Why?
|
| Affect | 6 | 2022 | 390 | 0.870 |
Why?
|
| Growth Hormone | 2 | 2015 | 96 | 0.850 |
Why?
|
| Male | 69 | 2022 | 43796 | 0.840 |
Why?
|
| Substance-Related Disorders | 2 | 2017 | 424 | 0.790 |
Why?
|
| Homovanillic Acid | 3 | 2012 | 35 | 0.790 |
Why?
|
| Hydroxyindoleacetic Acid | 3 | 2012 | 26 | 0.780 |
Why?
|
| Female | 62 | 2022 | 47767 | 0.740 |
Why?
|
| Hostility | 3 | 2021 | 25 | 0.740 |
Why?
|
| Parent-Child Relations | 3 | 2015 | 81 | 0.710 |
Why?
|
| Social Behavior | 4 | 2018 | 302 | 0.660 |
Why?
|
| Benzazepines | 1 | 2019 | 65 | 0.640 |
Why?
|
| Humans | 77 | 2022 | 92134 | 0.620 |
Why?
|
| Cognition | 4 | 2022 | 594 | 0.620 |
Why?
|
| Statistics as Topic | 6 | 2015 | 234 | 0.610 |
Why?
|
| Affective Symptoms | 2 | 2018 | 51 | 0.600 |
Why?
|
| Surveys and Questionnaires | 9 | 2019 | 2721 | 0.600 |
Why?
|
| Fluoxetine | 4 | 2015 | 41 | 0.590 |
Why?
|
| Violence | 1 | 2020 | 155 | 0.580 |
Why?
|
| Endocannabinoids | 1 | 2018 | 31 | 0.570 |
Why?
|
| Comorbidity | 8 | 2020 | 978 | 0.540 |
Why?
|
| Perforant Pathway | 1 | 2016 | 6 | 0.530 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2015 | 6 | 0.510 |
Why?
|
| Clonidine | 1 | 2015 | 33 | 0.510 |
Why?
|
| Middle Aged | 27 | 2020 | 26991 | 0.490 |
Why?
|
| White Matter | 1 | 2016 | 85 | 0.480 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 1905 | 0.480 |
Why?
|
| Interpersonal Relations | 1 | 2016 | 178 | 0.470 |
Why?
|
| Craving | 3 | 2020 | 23 | 0.460 |
Why?
|
| Object Attachment | 1 | 2014 | 19 | 0.460 |
Why?
|
| Brain | 6 | 2019 | 2334 | 0.450 |
Why?
|
| Smokers | 3 | 2020 | 50 | 0.450 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2016 | 333 | 0.440 |
Why?
|
| Personality Inventory | 6 | 2015 | 109 | 0.420 |
Why?
|
| Double-Blind Method | 10 | 2022 | 1751 | 0.410 |
Why?
|
| Amygdala | 3 | 2019 | 87 | 0.400 |
Why?
|
| Hydrocortisone | 2 | 2011 | 304 | 0.400 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 270 | 0.400 |
Why?
|
| Mental Processes | 1 | 2012 | 32 | 0.390 |
Why?
|
| Mood Disorders | 1 | 2012 | 83 | 0.380 |
Why?
|
| Pituitary-Adrenal Function Tests | 1 | 2011 | 2 | 0.380 |
Why?
|
| Spinal Puncture | 8 | 2015 | 39 | 0.370 |
Why?
|
| Suicide | 2 | 2016 | 151 | 0.370 |
Why?
|
| Adolescent | 14 | 2022 | 9488 | 0.370 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2011 | 131 | 0.360 |
Why?
|
| GABA-B Receptor Agonists | 1 | 2010 | 5 | 0.360 |
Why?
|
| Receptors, GABA-B | 1 | 2010 | 7 | 0.360 |
Why?
|
| Baclofen | 1 | 2010 | 16 | 0.360 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 12 | 2015 | 220 | 0.350 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2016 | 118 | 0.330 |
Why?
|
| Life Change Events | 3 | 2006 | 48 | 0.330 |
Why?
|
| Oxidative Stress | 3 | 2020 | 467 | 0.320 |
Why?
|
| Tobacco Products | 2 | 2020 | 67 | 0.310 |
Why?
|
| Spouse Abuse | 1 | 2008 | 13 | 0.310 |
Why?
|
| Suicide, Attempted | 4 | 2016 | 136 | 0.310 |
Why?
|
| Analysis of Variance | 6 | 2016 | 899 | 0.310 |
Why?
|
| Tryptophan | 3 | 2016 | 100 | 0.300 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2008 | 85 | 0.290 |
Why?
|
| Stress, Psychological | 1 | 2010 | 328 | 0.280 |
Why?
|
| Behavior, Addictive | 2 | 2020 | 135 | 0.280 |
Why?
|
| Heart Rate | 4 | 2020 | 502 | 0.270 |
Why?
|
| Healthy Volunteers | 3 | 2022 | 146 | 0.260 |
Why?
|
| Neurotransmitter Agents | 3 | 2013 | 108 | 0.260 |
Why?
|
| Antisocial Personality Disorder | 2 | 2018 | 92 | 0.250 |
Why?
|
| Serotonin Agents | 2 | 2015 | 13 | 0.230 |
Why?
|
| Fenfluramine | 2 | 2010 | 20 | 0.230 |
Why?
|
| Linear Models | 4 | 2016 | 427 | 0.230 |
Why?
|
| Smoking | 2 | 2020 | 640 | 0.220 |
Why?
|
| Adult Survivors of Child Abuse | 2 | 2015 | 14 | 0.220 |
Why?
|
| C-Reactive Protein | 5 | 2016 | 198 | 0.220 |
Why?
|
| Cross-Over Studies | 2 | 2022 | 389 | 0.220 |
Why?
|
| Frontal Lobe | 2 | 2017 | 131 | 0.210 |
Why?
|
| Administration, Intranasal | 6 | 2020 | 139 | 0.200 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 2 | 2014 | 71 | 0.200 |
Why?
|
| Personality | 2 | 2016 | 138 | 0.200 |
Why?
|
| Suicidal Ideation | 4 | 2016 | 74 | 0.200 |
Why?
|
| Self-Injurious Behavior | 3 | 2010 | 114 | 0.200 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 1767 | 0.200 |
Why?
|
| Inflammation | 4 | 2016 | 1020 | 0.190 |
Why?
|
| Interleukin-6 | 4 | 2016 | 270 | 0.190 |
Why?
|
| Cannabis | 1 | 2022 | 35 | 0.190 |
Why?
|
| Pilot Projects | 3 | 2019 | 894 | 0.190 |
Why?
|
| Caffeine | 1 | 2021 | 84 | 0.180 |
Why?
|
| Self Report | 3 | 2018 | 307 | 0.180 |
Why?
|
| Crime | 1 | 2001 | 37 | 0.180 |
Why?
|
| Neuropsychological Tests | 4 | 2016 | 519 | 0.180 |
Why?
|
| Child | 7 | 2014 | 7311 | 0.180 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 2 | 2011 | 48 | 0.170 |
Why?
|
| Narcissism | 1 | 2020 | 3 | 0.170 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2019 | 15 | 0.170 |
Why?
|
| Twins | 2 | 2017 | 65 | 0.170 |
Why?
|
| Administration, Oral | 3 | 2010 | 674 | 0.170 |
Why?
|
| Social Class | 1 | 2020 | 139 | 0.160 |
Why?
|
| Smoking Cessation | 2 | 2020 | 265 | 0.160 |
Why?
|
| Psychomotor Performance | 2 | 2022 | 498 | 0.160 |
Why?
|
| Social Desirability | 1 | 2018 | 12 | 0.150 |
Why?
|
| Cigarette Smoking | 1 | 2019 | 37 | 0.150 |
Why?
|
| Deception | 1 | 2018 | 20 | 0.150 |
Why?
|
| Polyunsaturated Alkamides | 1 | 2018 | 8 | 0.150 |
Why?
|
| Glycerides | 1 | 2018 | 17 | 0.150 |
Why?
|
| Arachidonic Acids | 1 | 2018 | 41 | 0.150 |
Why?
|
| Awareness | 1 | 2018 | 89 | 0.140 |
Why?
|
| Stress, Physiological | 1 | 2020 | 247 | 0.140 |
Why?
|
| Case-Control Studies | 5 | 2016 | 1891 | 0.140 |
Why?
|
| Deoxyguanosine | 2 | 2015 | 28 | 0.140 |
Why?
|
| Gray Matter | 1 | 2017 | 36 | 0.140 |
Why?
|
| Personality Assessment | 2 | 2014 | 97 | 0.140 |
Why?
|
| Prevalence | 2 | 2020 | 1289 | 0.140 |
Why?
|
| Intelligence Tests | 2 | 2014 | 38 | 0.140 |
Why?
|
| Biomarkers | 7 | 2016 | 1833 | 0.140 |
Why?
|
| Motion Pictures | 1 | 2016 | 12 | 0.140 |
Why?
|
| Recurrence | 1 | 2020 | 1179 | 0.130 |
Why?
|
| Sex Factors | 1 | 2020 | 1090 | 0.130 |
Why?
|
| Anisotropy | 1 | 2016 | 63 | 0.130 |
Why?
|
| United States | 2 | 2020 | 7312 | 0.130 |
Why?
|
| Kynurenine | 1 | 2016 | 21 | 0.130 |
Why?
|
| Brain Mapping | 4 | 2021 | 574 | 0.130 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2016 | 69 | 0.130 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 304 | 0.130 |
Why?
|
| Risk | 1 | 2017 | 663 | 0.120 |
Why?
|
| Valproic Acid | 1 | 2015 | 24 | 0.120 |
Why?
|
| Anxiety | 1 | 2018 | 324 | 0.120 |
Why?
|
| Citalopram | 1 | 2015 | 20 | 0.120 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 276 | 0.120 |
Why?
|
| Toxoplasmosis | 1 | 2016 | 66 | 0.120 |
Why?
|
| Facial Recognition | 1 | 2015 | 16 | 0.120 |
Why?
|
| Receptors, Interleukin-1 Type II | 1 | 2015 | 3 | 0.120 |
Why?
|
| Oxytocics | 3 | 2020 | 25 | 0.120 |
Why?
|
| Psychotropic Drugs | 1 | 2015 | 80 | 0.120 |
Why?
|
| Alcoholism | 1 | 2016 | 184 | 0.120 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 160 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2022 | 3480 | 0.110 |
Why?
|
| Dinoprost | 1 | 2014 | 26 | 0.110 |
Why?
|
| Blood Platelets | 2 | 2011 | 152 | 0.110 |
Why?
|
| Depression | 1 | 2018 | 525 | 0.110 |
Why?
|
| Glutamic Acid | 1 | 2013 | 156 | 0.100 |
Why?
|
| Neuropeptide Y | 1 | 2012 | 32 | 0.100 |
Why?
|
| Psychological Tests | 2 | 2010 | 91 | 0.100 |
Why?
|
| Biogenic Monoamines | 1 | 2012 | 9 | 0.100 |
Why?
|
| Substance P | 1 | 2012 | 62 | 0.100 |
Why?
|
| Time Factors | 4 | 2014 | 5425 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 606 | 0.100 |
Why?
|
| Radioligand Assay | 1 | 2011 | 32 | 0.100 |
Why?
|
| Receptors, Serotonin, 5-HT2 | 1 | 2011 | 15 | 0.100 |
Why?
|
| Hippocampus | 1 | 2015 | 444 | 0.100 |
Why?
|
| Neurotic Disorders | 1 | 2011 | 13 | 0.090 |
Why?
|
| Harm Reduction | 1 | 2011 | 24 | 0.090 |
Why?
|
| Amino Acids | 1 | 2012 | 254 | 0.090 |
Why?
|
| Parents | 1 | 2014 | 296 | 0.090 |
Why?
|
| Serotonin 5-HT1 Receptor Agonists | 1 | 2010 | 4 | 0.090 |
Why?
|
| Sex Characteristics | 1 | 2012 | 330 | 0.080 |
Why?
|
| Dexamethasone | 1 | 2011 | 347 | 0.080 |
Why?
|
| Diet | 1 | 2012 | 448 | 0.080 |
Why?
|
| Amino Acids, Neutral | 1 | 2008 | 3 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2010 | 595 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2011 | 578 | 0.070 |
Why?
|
| Verbal Behavior | 1 | 2008 | 32 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1939 | 0.070 |
Why?
|
| Social Environment | 2 | 2006 | 187 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2010 | 374 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 3766 | 0.070 |
Why?
|
| Reaction Time | 2 | 2022 | 312 | 0.060 |
Why?
|
| Subarachnoid Space | 1 | 2005 | 17 | 0.060 |
Why?
|
| Risk Factors | 4 | 2015 | 5683 | 0.060 |
Why?
|
| Pituitary-Adrenal System | 1 | 2005 | 64 | 0.060 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2005 | 81 | 0.060 |
Why?
|
| Methoxyhydroxyphenylglycol | 1 | 2003 | 18 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2006 | 302 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2016 | 8689 | 0.050 |
Why?
|
| Prolactin | 1 | 2003 | 89 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2003 | 172 | 0.050 |
Why?
|
| Blood Pressure | 2 | 2020 | 908 | 0.050 |
Why?
|
| Behavior | 1 | 2003 | 83 | 0.050 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2022 | 11 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 661 | 0.050 |
Why?
|
| Psilocybin | 1 | 2021 | 3 | 0.050 |
Why?
|
| Dronabinol | 1 | 2022 | 56 | 0.050 |
Why?
|
| Paroxetine | 2 | 2011 | 26 | 0.040 |
Why?
|
| Parenting | 2 | 2015 | 74 | 0.040 |
Why?
|
| Evoked Potentials | 1 | 2021 | 191 | 0.040 |
Why?
|
| Age Factors | 1 | 2005 | 1898 | 0.040 |
Why?
|
| Nicotine | 1 | 2021 | 204 | 0.040 |
Why?
|
| Prefrontal Cortex | 1 | 2001 | 139 | 0.040 |
Why?
|
| Models, Biological | 1 | 2006 | 1784 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 2456 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1762 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2017 | 2972 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 2390 | 0.030 |
Why?
|
| Kynurenic Acid | 1 | 2016 | 7 | 0.030 |
Why?
|
| Quinolinic Acid | 1 | 2016 | 9 | 0.030 |
Why?
|
| Picolinic Acids | 1 | 2016 | 8 | 0.030 |
Why?
|
| Self Concept | 2 | 2008 | 135 | 0.030 |
Why?
|
| Irritable Mood | 1 | 2015 | 10 | 0.030 |
Why?
|
| Tobacco Use Disorder | 1 | 2016 | 116 | 0.030 |
Why?
|
| Cues | 1 | 2016 | 177 | 0.030 |
Why?
|
| Interleukins | 1 | 2015 | 132 | 0.030 |
Why?
|
| Organ Size | 1 | 2015 | 375 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 479 | 0.030 |
Why?
|
| Dopamine | 1 | 2015 | 273 | 0.030 |
Why?
|
| Animals | 2 | 2019 | 28052 | 0.030 |
Why?
|
| Personality Tests | 1 | 2012 | 21 | 0.030 |
Why?
|
| Choice Behavior | 1 | 2014 | 162 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2013 | 309 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2012 | 155 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2016 | 423 | 0.020 |
Why?
|
| Tritium | 1 | 2011 | 133 | 0.020 |
Why?
|
| Multilevel Analysis | 1 | 2011 | 24 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 707 | 0.020 |
Why?
|
| Avoidance Learning | 1 | 2011 | 18 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2011 | 220 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 2011 | 135 | 0.020 |
Why?
|
| Cytokines | 1 | 2015 | 838 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 305 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2011 | 161 | 0.020 |
Why?
|
| Synaptic Membranes | 1 | 2010 | 14 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2014 | 757 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 1266 | 0.020 |
Why?
|
| Games, Experimental | 1 | 2009 | 11 | 0.020 |
Why?
|
| Child Development | 1 | 2011 | 167 | 0.020 |
Why?
|
| Body Temperature | 1 | 2010 | 127 | 0.020 |
Why?
|
| Intelligence | 1 | 2009 | 71 | 0.020 |
Why?
|
| Dendrites | 1 | 2010 | 103 | 0.020 |
Why?
|
| Electroshock | 1 | 2008 | 17 | 0.020 |
Why?
|
| Beverages | 1 | 2008 | 16 | 0.020 |
Why?
|
| Capsules | 1 | 2008 | 38 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 375 | 0.020 |
Why?
|
| Pain Threshold | 1 | 2008 | 61 | 0.020 |
Why?
|
| Aged | 2 | 2016 | 19913 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 868 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2008 | 358 | 0.020 |
Why?
|
| Binding Sites | 1 | 2009 | 1132 | 0.020 |
Why?
|
| Sexual Maturation | 1 | 2005 | 35 | 0.010 |
Why?
|
| Decision Making | 1 | 2009 | 679 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2005 | 3809 | 0.010 |
Why?
|